Based in France, ETAP-Lab is a Contract Research Organization (CRO) providing its clients with preclinical services in the fields of Dermatology, Neurology and Health-Nutrition. The company offers a large portfolio of translational and reproducible in vivo models in rodents. With more than 2 decades of experience, ETAP-Lab has become a best-in-class service provider for top-tier Pharma, Medical device and Agri-food companies and obtained ISO9001:v2015 certification for all its preclinical services.
Thanks to a partnership with the renowned academic team PhIND (U1237, INSERM, Normandy university), ETAP-Lab has been also emerging as leader in the field of preclinical stroke research with a unique model portfolio proposed under the brand Strok@lliance.
ETAP-Lab is listening to its clients’ needs to offer the best suited and scientifically sound solutions. Thus, its team is able to develop and customize relevant models with high translational value that fit to client’s specific goals, from the proof-of-concept to the early development.
“ETAP-Lab provides original and translational models of Stroke and Alzheimer’s disease, through technology transfer from world-class academic teams in the field”
In January 2019, ETAP-Lab expanded its services with a new in vitro activity focused on neurodegenerative diseases. To this end, ETAP-Lab created an in vitro laboratory which they needed to equip with the latest technologies, including a multi-mode microplate reader. The team needed the flexibility to be able to perform a wide variety of assays for their clients in the fastest possible time, including fluorescence, luminescence, absorbance and western blot detection measurements.
ETAP-Lab’s scientists chose the SpectraMax® i3x Multi-Mode Microplate Reader and SoftMax® Pro Software because they allow multi-mode measurements and provide them with greater flexibility than other systems.
The team performs fluorescence, luminescence and absorbance measurements to increase efficiency when testing cell confluence, cell viability and screening for new drug candidates for Alzheimer’s disease and Parkinson’s diseases. Scientists in ETAP-Lab are also using the ScanLater™ Western Blot Detection Cartridge module as a tool to shorten the investigation of both protein expression levels and signalling pathways of interest for their clients.
“The SpectraMax i3x Multi-Mode Microplate Reader and SoftMax Pro Software provide greater flexibility than other systems”.
The SpectraMax i3x Multi-Mode Microplate Reader measures absorbance, fluorescence, and luminescence with available upgrades including western blot, cell imaging, and fast kinetics with injectors plus additional detection modes. User-configurable detection modules provide the ability for exploring cellular pathways and protein expression.
ETAP Lab’s in vitro laboratory is now fully equipped. After an extensive validation process, ETAP-Lab is already producing its first in vitro studies for several European biotech and pharma companies, screening their molecules for compounds with neuroprotective properties in primary neuron cell cultures challenged with Aβ or α-syn oligomers.